FIG. 5.
ABT-737 delays decline in synaptic potentials after injection of 20 µg/ml recombinant ΔN BCL-xL into the presynaptic terminal. A: examples of change in slope of postsynaptic potentials over time after injection of ΔN BCL-xL or ΔN BCL-xL/ABT-737 solution. B: combined data comparing the half time of rundown of synaptic function in ΔN BCL-xL-injected synapses vs. synapses injected with ΔN BCL-xL + ABT-737 (n = 3 for ΔN BCL-xL alone and n = 5 for ΔN BCL-xL/ABT-737.